VIVS VivoSim Labs (VIVS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001497253
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter
What the filings say about VIVS
Insiders, 180 days
+$2.8K net bought
1 buyer
VivoSim Labs insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, VivoSim Labs, INC. insiders bought a net $2.8K of stock across 2 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 10,000 shares held after it.
- No other insider bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Lialin Tony Serge bought about $2.8K of VIVS on Aug 31, 2026, the largest insider purchase at the company on our record; 6 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- No other insider sold within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Gobel David sold about $7.3K of VIVS on Nov 17, 2025, the largest insider sale at the company on our record; 6 funds added in the latest 13F quarter.2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$2.8K over 180 days
+$2.8K over 90 days
more than 64% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 92% of Pharma & Biotech
Revenue
-9.0% year over year
below 65% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch VIVS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-93.2%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VIVS: institutional holders (13F)
13F holdings, latest reported quarter
25,976 sh
$27.8K
18,500 sh
$19.8K
15,371 sh
$16.4K
11,817 sh
$12.6K
7,003 sh
$7.5K
Congress trades in VIVS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
VIVS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
VIVS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$32.2K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$16.4K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$5.3K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$1.3K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Murphy
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$866.0K
$779.7K
$217.6K
-99%
n/a
2024
$1.2M
$887.7K
$135.9K
-98%
n/a
2023
$681.1K
$595.6K
$343.1K
-89%
n/a
2022
$621.4K
$368.2K
$390.9K
-77%
n/a
2021
$1.3M
-$24.9K
$779.6K
-61%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $2.8K bought by insiders over 180 days, 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
VIVS financials
Revenue growth
-9.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$112.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM VIVS
| FY Mar 2026 | $131.0K |
| FY Mar 2025 | $144.0K |
| FY Mar 2024 | $109.0K |
| FY Mar 2023 | $370.0K |
| FY Mar 2022 | n/a |
| Jun 2026 | $18.0K |
| Mar 2026 | $40.0K |
| Dec 2025 | $26.0K |
| Sep 2025 | $28.0K |
| Jun 2025 | $37.0K |
| Mar 2025 | $51.0K |
| Dec 2024 | $24.0K |
| Sep 2024 | $30.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM VIVS
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$10.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VIVS
| FY Mar 2026 | -$10.8M |
| FY Mar 2025 | -$9.5M |
| FY Mar 2024 | -$14.7M |
| FY Mar 2023 | -$12.8M |
| FY Mar 2022 | -$8.9M |
| Jun 2026 | -$3.2M |
| Mar 2026 | -$2.2M |
| Dec 2025 | -$2.3M |
| Sep 2025 | -$2.4M |
| Jun 2025 | -$3.9M |
| Mar 2025 | -$2.0M |
| Dec 2024 | -$1.8M |
| Sep 2024 | -$2.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity VIVS
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt VIVS
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-343.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity VIVS
| FY Mar 2026 | -294.8% |
| FY Mar 2025 | -35.3% |
| FY Mar 2024 | -155.0% |
| FY Mar 2023 | -75.8% |
| FY Mar 2022 | -33.0% |
| Jun 2026 | -343.1% |
| Mar 2026 | -294.8% |
| Dec 2025 | -51.1% |
| Sep 2025 | -36.9% |
| Jun 2025 | -24.5% |
| Mar 2025 | -35.3% |
| Dec 2024 | -378.4% |
| Sep 2024 | -206.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-155.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VIVS
| FY Mar 2026 | -125.6% |
| FY Mar 2025 | -23.7% |
| FY Mar 2024 | -110.1% |
| FY Mar 2023 | -64.4% |
| FY Mar 2022 | -31.3% |
| Jun 2026 | -155.9% |
| Mar 2026 | -125.6% |
| Dec 2025 | -22.7% |
| Sep 2025 | -24.1% |
| Jun 2025 | -18.5% |
| Mar 2025 | -23.7% |
| Dec 2024 | -194.7% |
| Sep 2024 | -140.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital VIVS
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-192.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed VIVS
| FY Mar 2026 | -148.1% |
| FY Mar 2025 | -163.8% |
| FY Mar 2024 | -142.8% |
| FY Mar 2023 | -73.0% |
| FY Mar 2022 | -32.3% |
| Jun 2026 | -192.2% |
| Mar 2026 | -148.1% |
| Dec 2025 | -424.9% |
| Sep 2025 | -210.3% |
| Jun 2025 | -140.6% |
| Mar 2025 | -163.8% |
| Dec 2024 | -310.5% |
| Sep 2024 | -183.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing VIVS
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 1.03x |
| Sep 2025 | 5.84x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value VIVS
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-454.4%
TTM free cash flow over market value at close 2026-10-27
FCF yield VIVS
| FY Mar 2026 | -290.3% |
| FY Mar 2025 | -24.2% |
| FY Mar 2024 | -11.8% |
| FY Mar 2023 | -5.6% |
| FY Mar 2022 | -2.3% |
| Jun 2026 | -362.8% |
| Mar 2026 | -290.3% |
| Dec 2025 | -225.1% |
| Sep 2025 | -133.8% |
| Jun 2025 | -272.9% |
| Mar 2025 | -24.2% |
| Dec 2024 | -11.9% |
| Sep 2024 | -12.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing VIVS
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-03 | |
|---|---|---|---|---|
| Revenue | $131.0K | $144.0K | $109.0K | $370.0K |
| Operating income | -$11.5M | -$12.6M | -$15.1M | -$17.7M |
| Net income | -$13.8M | -$2.5M | -$14.7M | -$17.3M |
| EPS (diluted) | -5.35 | -1.70 | -19.25 | -1.98 |
| Operating cash flow | -$10.8M | -$9.5M | -$14.7M | -$12.4M |
| Cash | $5.0M | $11.3M | $2.9M | $15.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
VIVS Stock Sonar score 5/7 axes
Find similar shapesCompareVIVS ranks highest on risk and compliance (61st percentile) and insider conviction (59th), and lowest on institutional and government (7th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VIVS filings, in plain words
Are VivoSim Labs insiders buying or selling VIVS?
In the 180 days to 2026-10-28, VivoSim Labs insiders were net buyers, a net $2.8K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, VivoSim Labs insiders were net buyers of VIVS, a net $2.8K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
